IL159576A0 - Pharmaceutical formulation for the intramuscular administration of fulvestrant - Google Patents
Pharmaceutical formulation for the intramuscular administration of fulvestrantInfo
- Publication number
- IL159576A0 IL159576A0 IL15957602A IL15957602A IL159576A0 IL 159576 A0 IL159576 A0 IL 159576A0 IL 15957602 A IL15957602 A IL 15957602A IL 15957602 A IL15957602 A IL 15957602A IL 159576 A0 IL159576 A0 IL 159576A0
- Authority
- IL
- Israel
- Prior art keywords
- fulvestrant
- pharmaceutical formulation
- intramuscular administration
- intramuscular
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0116619.8A GB0116619D0 (en) | 2001-07-07 | 2001-07-07 | Formulation |
| US31571101P | 2001-08-30 | 2001-08-30 | |
| PCT/GB2002/003092 WO2003006064A1 (en) | 2001-07-07 | 2002-07-03 | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL159576A0 true IL159576A0 (en) | 2004-06-01 |
Family
ID=26246290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15957602A IL159576A0 (en) | 2001-07-07 | 2002-07-03 | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1406662A1 (ru) |
| JP (1) | JP2004534093A (ru) |
| CN (1) | CN1553815A (ru) |
| AR (1) | AR037138A1 (ru) |
| BR (1) | BR0210898A (ru) |
| CA (1) | CA2453111A1 (ru) |
| CO (1) | CO5560585A2 (ru) |
| HU (1) | HUP0400115A3 (ru) |
| IL (1) | IL159576A0 (ru) |
| IS (1) | IS7097A (ru) |
| MX (1) | MXPA04000028A (ru) |
| NO (1) | NO20040047L (ru) |
| PL (1) | PL367624A1 (ru) |
| RU (1) | RU2004102393A (ru) |
| WO (1) | WO2003006064A1 (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| CN102264372B (zh) | 2009-08-31 | 2012-07-11 | 西安力邦医药科技有限责任公司 | 氟维司群纳米球/微球及其制备方法和用途 |
| CN102600073B (zh) * | 2012-03-31 | 2014-01-01 | 莱普德制药有限公司 | 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法 |
| CN102600065B (zh) * | 2012-03-31 | 2014-08-13 | 莱普德制药有限公司 | 一种氟维司群或其衍生物油性制剂及其制备方法 |
| CN102600064A (zh) * | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| EP3441073B1 (en) * | 2016-04-06 | 2022-02-23 | FUJIFILM Corporation | Medicinal composition comprising fulvestrant |
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| EP3452011A1 (en) * | 2016-05-06 | 2019-03-13 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| WO2017208847A1 (ja) | 2016-05-31 | 2017-12-07 | 富士フイルム株式会社 | 医薬組成物 |
| IL274433B2 (en) * | 2017-11-08 | 2024-07-01 | Eagle Pharmaceuticals Inc | Fulvestrant formulations and methods of using them |
| US20210169897A1 (en) * | 2017-12-07 | 2021-06-10 | Nevakar Inc. | Concentrated Fulvestrant Compositions |
| CN111465398A (zh) * | 2018-01-31 | 2020-07-28 | 富士胶片株式会社 | 注射用制剂的制造方法 |
| CN111481559B (zh) * | 2019-01-25 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种高浓度的氟维司群组合物及其制备方法 |
| EP4074304A4 (en) * | 2019-12-11 | 2024-01-10 | Shanghai Bocimed Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
| GB9525194D0 (en) * | 1995-12-12 | 1996-02-07 | Zeneca Ltd | Pharmaceutical composition |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| GB0008172D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
-
2002
- 2002-07-03 IL IL15957602A patent/IL159576A0/xx unknown
- 2002-07-03 WO PCT/GB2002/003092 patent/WO2003006064A1/en not_active Application Discontinuation
- 2002-07-03 RU RU2004102393/15A patent/RU2004102393A/ru not_active Application Discontinuation
- 2002-07-03 BR BR0210898-4A patent/BR0210898A/pt not_active IP Right Cessation
- 2002-07-03 PL PL02367624A patent/PL367624A1/xx not_active Application Discontinuation
- 2002-07-03 JP JP2003511869A patent/JP2004534093A/ja active Pending
- 2002-07-03 CN CNA028171888A patent/CN1553815A/zh active Pending
- 2002-07-03 CA CA002453111A patent/CA2453111A1/en not_active Abandoned
- 2002-07-03 EP EP02740940A patent/EP1406662A1/en not_active Withdrawn
- 2002-07-03 HU HU0400115A patent/HUP0400115A3/hu unknown
- 2002-07-05 AR ARP020102523A patent/AR037138A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 IS IS7097A patent/IS7097A/is unknown
- 2004-01-06 NO NO20040047A patent/NO20040047L/no not_active Application Discontinuation
- 2004-01-07 CO CO04000761A patent/CO5560585A2/es not_active Application Discontinuation
- 2004-01-07 MX MXPA04000028A patent/MXPA04000028A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0400115A2 (hu) | 2004-06-28 |
| AR037138A1 (es) | 2004-10-27 |
| NO20040047L (no) | 2004-02-23 |
| HUP0400115A3 (en) | 2005-11-28 |
| MXPA04000028A (es) | 2004-05-21 |
| WO2003006064A1 (en) | 2003-01-23 |
| CN1553815A (zh) | 2004-12-08 |
| RU2004102393A (ru) | 2005-03-27 |
| CO5560585A2 (es) | 2005-09-30 |
| BR0210898A (pt) | 2004-06-22 |
| JP2004534093A (ja) | 2004-11-11 |
| PL367624A1 (en) | 2005-03-07 |
| EP1406662A1 (en) | 2004-04-14 |
| IS7097A (is) | 2004-01-05 |
| CA2453111A1 (en) | 2003-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0302857A3 (en) | Pharmaceutical formulation | |
| HUP0401642A3 (en) | Use of staurosporine derivatives for the preparation of pharmaceutical compositions | |
| GB0118689D0 (en) | Pharmaceutical formulation | |
| HUP0204137A3 (en) | Pharmaceutical composition comprising fulvestrant | |
| HUP0400200A3 (en) | Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof | |
| PL366432A1 (en) | Pharmaceutical formulation | |
| AU2002257582A1 (en) | Pharmaceutical formulation | |
| IL159576A0 (en) | Pharmaceutical formulation for the intramuscular administration of fulvestrant | |
| EP1406493A4 (en) | ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER | |
| GB0103638D0 (en) | Pharmaceutical formulations | |
| IL161306A0 (en) | Pharmaceutical formulation comprising (r)-bicalutamide | |
| GB0105560D0 (en) | Pharmaceutical formulations | |
| HK1068277A1 (en) | Pharmaceutical compositions comprising chelidonineor derivatives thereof | |
| HUP0200253A3 (en) | Pharmaceutical compositions for combination therapy | |
| GB0201607D0 (en) | Formulation for the administration of medicinal substances | |
| GB0014851D0 (en) | Novel pharmaceutical formulation | |
| GB0104749D0 (en) | Pharmaceutical formulation | |
| GB0014883D0 (en) | Novel pharmaceutical formulation | |
| GB0014947D0 (en) | Novel pharmaceutical formulation | |
| GB0014892D0 (en) | Novel pharmaceutical formulation | |
| GB0317345D0 (en) | Formulation for the administration of medicinal substances | |
| GB0124712D0 (en) | Pharmaceutical formulation | |
| EP1414417A4 (en) | PHARMACEUTICAL FORMULATION | |
| HUP0103049A3 (en) | Use of fluexetine for preparation of pharmaceutical compositions | |
| GB0014869D0 (en) | Novel pharmaceutical formulation |